Ulrik Niels Lassen
Clinical Professor
- 2022
- Published
Late effects–the new focus of follow-up
Johansen, Christoffer, von Heymann, A., Rafn, B. S., Borgquist, S., Christiansen, P., Christensen, P., Zachariae, R., Pappot, Helle & Lassen, Ulrik Niels, 2022, In: Acta Oncologica. 61, 10, p. 1163-1164Research output: Contribution to journal › Editorial › Research
- Published
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
Rafaeva, Maria, Horton, E. R., Jensen, A. R. D., Madsen, C. D., Reuten, R., Willacy, O., Brøchner, Christian Beltoft, Jensen, Thomas Hartvig Lindkær, Zornhagen, Kamilla Westarp, Crespo Bravo, Marina, Grønseth, D. S., Nielsen, S. R., Idorn, M., Straten, P. T., Rohrberg, K., Spanggaard, I., Højgaard, M., Lassen, Ulrik Niels, Erler, Janine & Mayorca Guiliani, Alejandro Enrique, 2022, In: Advanced Healthcare Materials. 11, 1, 2100684.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Patients in phase 1 cancer trials: psychological distress and understanding of trial information
Gad, K. T., Lassen, Ulrik Niels, Duun-Henriksen, A. K., Dalton, Susanne Oksbjerg, Mau-Sørensen, M., Bidstrup, P. E., Høeg, B. L., Rohrberg, K. S., Spanggard, I., von Heymann, A. & Johansen, Christoffer, 2022, In: Acta Oncologica. 61, 3, p. 341-348 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
Yang, J. C. H., Brose, M. S., Castro, G., Kim, E. S., Lassen, Ulrik Niels, Leyvraz, S., Pappo, A., López-Ríos, F., Reeves, J. A., Fellous, M., Penault-Llorca, F., Rudzinski, E. R., Tabatabai, G., Vassal, G., Drilon, A. & Trent, J., 2022, In: BMC Cancer. 22, 1, 625.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy
Eriksen, M., Yde, C. W., Ahlborn, L. B., Qvortrup, Camilla, Lassen, Ulrik Niels, Højgaard, M., Spanggaard, I. & Rohrberg, K. S., 2022, In: European Journal of Cancer. 174, S1, p. S118Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
- Published
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies
Lazar, V., Girard, N., Raymond, E., Martini, J., Galbraith, S., Raynaud, J., Bresson, C., Solomon, B., Magidi, S., Nechushtan, H., Onn, A., Berger, R., Chen, H., Al-omari, A., Ikeda, S., Lassen, U., Sekacheva, M., Felip, E., Tabernero, J., Batist, G. & 10 others, , 2022, In: JCO Precision Oncology. 6, 12 p., e2200072.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
Nørøxe, D. S., Flynn, A., Yde, C. W., Østrup, O., Nielsen, Finn Cilius, Skjøth, Jane, Brennum, J., Hamerlik, P., Weischenfeldt, Joachim Lütken, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2022, In: Molecular Oncology. 16, 1, p. 206-218Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study
Briggs, A., Paracha, N., Rosettie, K., Upton, A., Bokemeyer, C., Lassen, Ulrik Niels & Sullivan, S. D., Jan 2022, In: Oncology. 100, 2, p. 124–129 6 p.Research output: Contribution to journal › Letter › Research › peer-review
- 2023
- Published
Characteristics of de novo cancer in liver transplant recipients
Riis, T. H., Møller, D. L., Høgh, J., Knudsen, A. D., Rostved, A. A., Akdag, D., Kirkby, N., Lassen, Ulrik Niels, Rasmussen, A., Hillingsø, Jens Georg & Pommergaard, Hans-Christian L, 2023, In: APMIS. 131, 4, p. 135-141 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J-Y., Italiano, A., Yonemori, K., Cho, D. C., de Vos, F. Y. F. L., Moreau, P., Fernandez, E. E., Schellens, J. H. M., Zielinski, C. C., Redhu, S., Boran, A. & 3 others, , 2023, In: Nature Medicine. 29, 5, p. 1103-1112 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4952653
Most downloads
-
481
downloads
Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
224
downloads
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
175
downloads
Hallmarks of glioblastoma: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Published